PSNL News and Press, Personalis Inc. From 07/12/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013. US Patent No. 11,384,394 describes the detection of MRD and recurrence by using who...

Today, we profile Personalis, a small cancer genomics testing firm. The stock has taken a battering in 2022 and is posting substantial quarterly losses, but shares now sell for less than net cash. 2022 is a transition year for the company in many ways. An investment analysis ...

Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...

Personalis, Inc. (PSNL) Q1 2022 Earnings Conference Call May 4, 2022, 5:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President and CEO Aaron Tachibana - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Max Masucci - Cowen Mark Mass...

Personalis press release (NASDAQ:PSNL): Q1 GAAP EPS of -$0.63 misses by $0.03. Revenue of $15.23M (-27.1% Y/Y) beats by $0.81M. Shares -2.1%. Full year 2022 Outlook:  Total company revenue is expected to be in the range of $62.0 million to $67.0 million vs. estimates of $67.15. Revenue f...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Reported quarterly revenue of $15.2 million in the first quarter of 2022 ...

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combin...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position of Vice President of Diagnostic Sales. This appointment supports the company’s objective to accelerate expansion in...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. P...

Tool detects increasingly important biomarker for immunotherapy Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, " A machine learning algorithm with subclonal sensitivity reveals wid...